The Role of T Cell Immunotherapy in Acute Myeloid Leukemia

Overview

Journal Cells

Publisher MDPI

Specialties Biochemistry
Biophysics
Cell Biology
Molecular Biology

Date 2021 Dec 24

PMID 34943884

Citations 17

Authors

Fang Hao

Christine Sholy

Chen Wang

Min Cao

Xunlei Kang

Affiliations

Soon will be listed here.

Abstract

Acute myeloid leukemia (AML) is a heterogeneous disease associated with various alterations in T cell phenotype and function leading to an abnormal cell population, ultimately leading to immune exhaustion. However, restoration of T cell function allows for the execution of cytotoxic mechanisms against leukemic cells in AML patients. Therefore, long-term disease control, which requires multiple therapeutic approaches, includes those aimed at the re-establishment of cytotoxic T cell activity. AML treatments that harness the power of T lymphocytes against tumor cells have rapidly evolved over the last 3 to 5 years through various stages of preclinical and clinical development. These include tissue-infiltrated lymphocytes (TILs), bispecific antibodies, immune checkpoint inhibitors (ICIs), chimeric antigen receptor T (CAR-T) cell therapy, and tumor-specific T cell receptor gene-transduced T (TCR-T) cells. In this review, these T cell-based immunotherapies and the potential of TILs as a novel antileukemic therapy will be discussed.

Citing Articles

Immunoediting in acute myeloid leukemia: Reappraising T cell exhaustion and the aberrant antigen processing machinery in leukemogenesis.

Wang C, Lin S, Chang K, Cheong H, Wu S, Lee C Heliyon. 2024; 10(21):e39731.

PMID: 39568858 PMC: 11577197. DOI: 10.1016/j.heliyon.2024.e39731.

Immune-dysregulation harnessing in myeloid neoplasms.

Sharifi M, Xu L, Nasiri N, Ashja-Arvan M, Soleimanzadeh H, Ganjalikhani-Hakemi M Cancer Med. 2024; 13(17):e70152.

PMID: 39254117 PMC: 11386321. DOI: 10.1002/cam4.70152.

The Immune Resistance Signature of Acute Myeloid Leukemia and Current Immunotherapy Strategies.

Chandra D, Alber B, Saultz J Cancers (Basel). 2024; 16(15).

PMID: 39123343 PMC: 11311077. DOI: 10.3390/cancers16152615.

Evaluation of the safety and efficiency of cytotoxic T cell therapy sensitized by tumor antigens original from T-ALL-iPSC in vivo.

Li W, Zhou M, Wang L, Huang L, Chen X, Sun X Cancer Innov. 2024; 3(1):e95.

PMID: 38948536 PMC: 11212296. DOI: 10.1002/cai2.95.

Higher TIGIT+ γδ T cells may predict poor prognosis in younger adult patients with non-acute promyelocytic AML.

Hou Q, Wang P, Kong X, Chen J, Yao C, Luo X Front Immunol. 2024; 15:1321126.

PMID: 38711501 PMC: 11070478. DOI: 10.3389/fimmu.2024.1321126.

References

Blazar B, Hill G, Murphy W . Dissecting the biology of allogeneic HSCT to enhance the GvT effect whilst minimizing GvHD. Nat Rev Clin Oncol. 2020; 17(8):475-492. PMC: 7901860. DOI: 10.1038/s41571-020-0356-4. View

Chapuis A, Egan D, Bar M, Schmitt T, McAfee M, Paulson K . T cell receptor gene therapy targeting WT1 prevents acute myeloid leukemia relapse post-transplant. Nat Med. 2019; 25(7):1064-1072. PMC: 6982533. DOI: 10.1038/s41591-019-0472-9. View

Kong Y, Zhu L, Schell T, Zhang J, Claxton D, Ehmann W . T-Cell Immunoglobulin and ITIM Domain (TIGIT) Associates with CD8+ T-Cell Exhaustion and Poor Clinical Outcome in AML Patients. Clin Cancer Res. 2016; 22(12):3057-66. DOI: 10.1158/1078-0432.CCR-15-2626. View

Sweeney C, Vyas P . The Graft-Versus-Leukemia Effect in AML. Front Oncol. 2019; 9:1217. PMC: 6877747. DOI: 10.3389/fonc.2019.01217. View

Lamble A, Lind E . Targeting the Immune Microenvironment in Acute Myeloid Leukemia: A Focus on T Cell Immunity. Front Oncol. 2018; 8:213. PMC: 6008423. DOI: 10.3389/fonc.2018.00213. View

Ghosh A, Barba P, Perales M . Checkpoint inhibitors in AML: are we there yet?. Br J Haematol. 2019; 188(1):159-167. PMC: 9549702. DOI: 10.1111/bjh.16358. View

Lin B, Du L, Li H, Zhu X, Cui L, Li X . Tumor-infiltrating lymphocytes: Warriors fight against tumors powerfully. Biomed Pharmacother. 2020; 132:110873. DOI: 10.1016/j.biopha.2020.110873. View

Liao D, Wang M, Liao Y, Li J, Niu T . A Review of Efficacy and Safety of Checkpoint Inhibitor for the Treatment of Acute Myeloid Leukemia. Front Pharmacol. 2019; 10:609. PMC: 6562221. DOI: 10.3389/fphar.2019.00609. View

Lowenberg B, Downing J, Burnett A . Acute myeloid leukemia. N Engl J Med. 1999; 341(14):1051-62. DOI: 10.1056/NEJM199909303411407. View

10.

Krupka C, Kufer P, Kischel R, Zugmaier G, Bogeholz J, Kohnke T . CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330. Blood. 2013; 123(3):356-65. DOI: 10.1182/blood-2013-08-523548. View

11.

Guy D, Uy G . Bispecific Antibodies for the Treatment of Acute Myeloid Leukemia. Curr Hematol Malig Rep. 2018; 13(6):417-425. PMC: 6295344. DOI: 10.1007/s11899-018-0472-8. View

12.

Qin Y, Zhu H, Jiang B, Li J, Lu X, Li L . Expression patterns of WT1 and PRAME in acute myeloid leukemia patients and their usefulness for monitoring minimal residual disease. Leuk Res. 2008; 33(3):384-90. DOI: 10.1016/j.leukres.2008.08.026. View

13.

Kassim A, Savani B . Hematopoietic stem cell transplantation for acute myeloid leukemia: A review. Hematol Oncol Stem Cell Ther. 2017; 10(4):245-251. DOI: 10.1016/j.hemonc.2017.05.021. View

14.

Ferrara J, Levine J, Reddy P, Holler E . Graft-versus-host disease. Lancet. 2009; 373(9674):1550-61. PMC: 2735047. DOI: 10.1016/S0140-6736(09)60237-3. View

15.

Graf C, Heidel F, Tenzer S, Radsak M, Solem F, Britten C . A neoepitope generated by an FLT3 internal tandem duplication (FLT3-ITD) is recognized by leukemia-reactive autologous CD8+ T cells. Blood. 2006; 109(7):2985-8. DOI: 10.1182/blood-2006-07-032839. View

16.

Knaus H, Berglund S, Hackl H, Blackford A, Zeidner J, Montiel-Esparza R . Signatures of CD8+ T cell dysfunction in AML patients and their reversibility with response to chemotherapy. JCI Insight. 2018; 3(21). PMC: 6238744. DOI: 10.1172/jci.insight.120974. View

17.

Ritchie D, Neeson P, Khot A, Peinert S, Tai T, Tainton K . Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemia. Mol Ther. 2013; 21(11):2122-9. PMC: 3831035. DOI: 10.1038/mt.2013.154. View

18.

Krupka C, Kufer P, Kischel R, Zugmaier G, Lichtenegger F, Kohnke T . Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism. Leukemia. 2015; 30(2):484-91. DOI: 10.1038/leu.2015.214. View

19.

Molica M, Perrone S, Mazzone C, Niscola P, Cesini L, Abruzzese E . CD33 Expression and Gentuzumab Ozogamicin in Acute Myeloid Leukemia: Two Sides of the Same Coin. Cancers (Basel). 2021; 13(13). PMC: 8268215. DOI: 10.3390/cancers13133214. View

20.

Zhou Q, Bucher C, Munger M, Highfill S, Tolar J, Munn D . Depletion of endogenous tumor-associated regulatory T cells improves the efficacy of adoptive cytotoxic T-cell immunotherapy in murine acute myeloid leukemia. Blood. 2009; 114(18):3793-802. PMC: 2773484. DOI: 10.1182/blood-2009-03-208181. View